These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2605102)

  • 1. Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
    Twelves CJ; O'Reilly SM; Coleman RE; Richards MA; Rubens RD
    Br J Cancer; 1989 Dec; 60(6):938-41. PubMed ID: 2605102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification.
    Twelves CJ; Richards MA; Smith P; Rubens RD
    Ann Oncol; 1991 Oct; 2(9):663-6. PubMed ID: 1742222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
    Twelves CJ; Dobbs NA; Michael Y; Summers LA; Gregory W; Harper PG; Rubens RD; Richards MA
    Br J Cancer; 1992 Oct; 66(4):765-9. PubMed ID: 1419619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.
    Dobbs NA; Twelves CJ; Gregory W; Cruickshanka C; Richards MA; Rubens RD
    Eur J Cancer; 2003 Mar; 39(5):580-6. PubMed ID: 12628836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective palliation of advanced breast cancer with weekly low dose epirubicin.
    Jones WG
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):357-60. PubMed ID: 2467808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.
    Dobbs NA; Twelves CJ; Rizzi P; Warwick JD; Metivier EM; Williams R; Johnson PJ
    Cancer Chemother Pharmacol; 1994; 34(5):405-10. PubMed ID: 8070007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
    Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
    Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
    Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
    Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
    Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
    Hui R; Zhang M; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
    Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
    Waters SH; Gillibrand A; Berry H; Kumar S; Velikova G; Dodwell DJ; Perren TJ
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):407-12. PubMed ID: 19455333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly epirubicin in the treatment of gestational breast cancer (GBC).
    Peccatori FA; Azim HA; Scarfone G; Gadducci A; Bonazzi C; Gentilini O; Galimberti V; Intra M; Locatelli M; Acaia B; Rossi P; Cinieri S; Calabrese L; Goldhirsch A
    Breast Cancer Res Treat; 2009 Jun; 115(3):591-4. PubMed ID: 18712595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
    Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
    J Clin Oncol; 1993 Mar; 11(3):467-73. PubMed ID: 8445422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
    J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
    Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
    Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
    Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
    Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.